These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 6104908

  • 1. Psychiatric effects of bromocriptine and lergotrile in Parkinsonian patients.
    Serby M, Angrist B, Lieberman A.
    Adv Biochem Psychopharmacol; 1980; 23():287-92. PubMed ID: 6104908
    [No Abstract] [Full Text] [Related]

  • 2. Mental disturbances during bromocriptine and lergotrile treatment of Parkinson's disease.
    Serby M, Angrist B, Lieberman A.
    Am J Psychiatry; 1978 Oct; 135(10):1227-9. PubMed ID: 29497
    [No Abstract] [Full Text] [Related]

  • 3. Comparison between lergotrile and bromocriptine in parkinsonism.
    Teychenne PF, Pfeiffer RF, Bern SM, McInturff D, Calne DB.
    Ann Neurol; 1978 Apr; 3(4):319-24. PubMed ID: 666273
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Clinical experience with bromocriptine, a central dopaminergic stimulator].
    Ludin HP, Kunz F, Lörincz P, Ringwald E.
    Nervenarzt; 1976 Nov; 47(11):651-5. PubMed ID: 794749
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Bromocriptine and lisuride in Parkinson disease.
    Lieberman AN, Gopinathan G, Neophytides A, Leibowitz M, Walker R, Hiesiger E.
    Ann Neurol; 1983 Jan; 13(1):44-7. PubMed ID: 6830164
    [Abstract] [Full Text] [Related]

  • 11. Lisuride treatment in Parkinson's disease: clinical and pharmacokinetic studies.
    LeWitt PA, Burns RS, Calne DB.
    Adv Neurol; 1983 Jan; 37():131-40. PubMed ID: 6344586
    [Abstract] [Full Text] [Related]

  • 12. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease.
    Lieberman AN, Neophytides A, Leibowitz M, Gopinathan G, Pact V, Walker R, Goodgold A, Goldstein M.
    Adv Neurol; 1983 Jan; 37():95-108. PubMed ID: 6858782
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic results with a new ergoline derivate (8-alpha-amino-ergoline, CU 32-085) in parkinsonian patients.
    Schneider E, Hubener K, Fischer PA.
    Adv Neurol; 1984 Jan; 40():527-9. PubMed ID: 6695631
    [No Abstract] [Full Text] [Related]

  • 14. [Letter: Efficacy of bromocriptine in 2 cases of levodopa-resistant parkinsonism].
    Kissel P, Andre JM, Jacquier A.
    Nouv Presse Med; 1976 Jan 24; 5(4):210. PubMed ID: 1264671
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical studies with bromocriptine in idiopathic parkinsonism.
    Teychenne PF, Kartzinel R, Perlow M, Pfeiffer R, Calne DB.
    Trans Am Neurol Assoc; 1976 Jan 24; 101():302-4. PubMed ID: 1037483
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Psychosis due to the interaction of erythromycin and bromocriptine in Parkinson disease].
    Alegre M, Noé E, Martínez Lage JM.
    Neurologia; 1997 Nov 24; 12(9):429. PubMed ID: 9471184
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Lergotrile in Parkinson disease: further studies.
    Lieberman AN, Gopinathan G, Estey E, Kupersmith M, Goodgold A, Goldstein M.
    Neurology; 1979 Feb 24; 29(2):267-72. PubMed ID: 34808
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.